129 results
424B3
ADIL
Adial Pharmaceuticals Inc
23 Apr 24
Prospectus supplement
4:00pm
for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other … research and development expenses to increase when we commence our clinical development program in the U.S. Even if we succeed in commercializing our product
424B5
ADIL
Adial Pharmaceuticals Inc
18 Apr 24
Prospectus supplement for primary offering
5:31pm
, and we continue to incur significant research and development and other expenses related to our ongoing operations. To date, we have not generated … an accumulated deficit of approximately $68.8 million.
We expect our research and development expenses to increase when we commence our clinical
8-K
EX-99.1
ADIL
Adial Pharmaceuticals Inc
6 Mar 24
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
4:21pm
necessary to fund our research and development activities, our ability to retain our key employees or maintain our Nasdaq listing, our ability to complete
8-K
EX-99.1
xq3v4vpr4rx540g
18 Jan 24
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
4:15pm
8-K
EX-99.1
yy55j79coq3ri67z3e
29 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:47pm
424B3
u7ywh9fqy4 cys5c8yy
20 Nov 23
Prospectus supplement
7:46am
8-K
EX-99.1
h2lncdu5c4iun2v
14 Nov 23
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
5:29pm
8-K
EX-99.2
hmvmfer
24 Oct 23
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:48pm
8-K
EX-99.1
rrpt9
24 Oct 23
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:48pm
8-K
EX-99.1
pgjxa6iv1 fobqgn
26 Sep 23
Other Events
9:08pm
8-K
EX-2.3
8hc48narv gxhz
21 Sep 23
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-99.1
5pfakw0i36xh9g
23 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:45am
8-K
EX-99.1
qx0nneq024qtmizh
21 Aug 23
Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8:46am